Most Read Articles
Rachel Soon, 16 Aug 2019

On 8 August, the first town hall held by the Ministry of Health (MOH) with members of the pharmacy profession took place in Putrajaya. Over 500 pharmacists from across the country and from different areas of practice—community and hospital, public and private, academy and industry—converged to fill the auditorium for the chance to engage in direct dialogue with MOH.

3 days ago
Cardiac biomarkers are useful for identifying community-acquired pneumonia (CAP) patients with an elevated risk of early and long-term cardiovascular (CV) events, according to a study.
Yesterday
Tofogliflozin is safe and effective for elderly patients with type 2 diabetes mellitus (T2DM), regardless of insulin and oral antidiabetic drugs, reports a new Japan study.
6 days ago
Pulmonary function has potential predictive value for future increases in arterial stiffness and its progression, as reported in a recent study.

Anti-TNFα trumps other treatments at preventing postoperative Crohn’s disease recurrence

10 Aug 2019
Crohn’s is not the end of the world, as Kathleen Baker’s silver medal proves

Anti-tumour necrosis factor α (anti-TNFα) agents are better than other conventional therapies at preventing the clinical, endoscopic and histological postoperative recurrence (POR) of Crohn’s disease (CD), reports a recent meta-analysis.

After applying the selection criteria, 14 studies emerged eligible for inclusion in the analysis, ten of which were randomized controlled trials (RCTs) by design. The resulting cumulative sample included 1,224 CD patient. Studies were retrieved from the databases of PubMed, Embase, CENTRAL and Web of Science.

The rate of clinical (odds ratio [OR], 0.508, 95 percent CI, 0.309–0.834; p=0.007), endoscopic (OR, 0.312; 0.199–0.489; p<0.001), severe endoscopic (OR, 0.195, 0.195–0.356; p<0.001) and histological (OR, 0.255, 0.106–0.611) POR was significantly lower in patients who were taking anti-TNFα as opposed to other nonbiological treatments.

In comparison, anti-TNFα therapy was significantly better than thiopurines only in terms of endoscopic POR (OR, 0.392, 0.241–0.639; p<0.001). Head-to-head comparison studies also showed that adalimumab and infliximab resulted in statistically comparable endoscopic POR rates (OR, 0.799, 0.329–1.940; p=0.620).

Eight of the included studies did not stratify patients according to risk groups. In this pooled sample of unselected CD patients, anti-TNFα treatment remained significantly better at preventing clinical (OR, 0.324, 0.158–0.664; p=0.002), endoscopic (OR, 0.225, 0.124–0.409; p<0.001) and severe endoscopic (OR, 0.248, 0.070–0.877) POR.

The relative efficacy of anti-TNFα therapies did not come at the cost of additional safety concerns, according to a pooled analysis of six studies. The rate of adverse (OR, 0.860, 0.457–1.617; p=0.639) and severe adverse (OR, 1.018, 0.641–1.617; p=0.94) events were comparable between patients who received anti-TNFα and other conventional treatments.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 16 Aug 2019

On 8 August, the first town hall held by the Ministry of Health (MOH) with members of the pharmacy profession took place in Putrajaya. Over 500 pharmacists from across the country and from different areas of practice—community and hospital, public and private, academy and industry—converged to fill the auditorium for the chance to engage in direct dialogue with MOH.

3 days ago
Cardiac biomarkers are useful for identifying community-acquired pneumonia (CAP) patients with an elevated risk of early and long-term cardiovascular (CV) events, according to a study.
Yesterday
Tofogliflozin is safe and effective for elderly patients with type 2 diabetes mellitus (T2DM), regardless of insulin and oral antidiabetic drugs, reports a new Japan study.
6 days ago
Pulmonary function has potential predictive value for future increases in arterial stiffness and its progression, as reported in a recent study.